Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 15/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 3/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 3/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 3/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PRKAB2 | O43741 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709614 | 1.00 | STK17B (1.00) | STK17BMEN1RECQLKMT2AAURKA | |
| SCHEMBL3709615 | 1.00 | STK17B (1.00) | STK17BMEN1RECQLKMT2AAURKA | |
| SCHEMBL21199305 | 0.87 | STK17B (0.76) | STK17BMEN1RECQLKMT2AAURKA | |
| SCHEMBL10921543 | 0.85 | STK17B (0.74) | STK17BMEN1RECQLKMT2AAURKA | |
| SCHEMBL19462733 | 0.84 | STK17B (0.89) | STK17BMEN1RECQLKMT2AAURKA | |
| SCHEMBL19499394 | 0.84 | STK17B (0.89) | STK17BMEN1RECQLKMT2AAURKA | |
| Sulfuretin SCHEMBL634006 | 0.84 | MEN1 (1.00) | STK17BMEN1RECQLKMT2AAURKA | |
| Sulfuretin SCHEMBL634007 | 0.84 | MEN1 (1.00) | STK17BMEN1RECQLKMT2AAURKA | |
| Sulfuretin SCHEMBL30214394 | 0.84 | MEN1 (1.00) | STK17BMEN1RECQLKMT2AAURKA | |
| SCHEMBL30337058 | 0.84 | STK17B (1.00) | STK17BMEN1RECQLKMT2AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024178274-A2 | METHODS OF DEGRADING RAF(RAF) PROTEIN IN CELLS USING MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1/2 (MEK1/2) PROTEIN DEGRADERS | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-3723801-B9 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | BIORA THERAPEUTICS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3723801-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | BIORA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115282165-A | Natural killer cells from placenta | 细胞结构公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115137753-A | Natural killer cells from placenta | 细胞结构公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | STK17B 2341/4885MEN1 306/4885RECQL 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.